

Form PTO-1449 (Rev. 2-88)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 2132.030		APPLICATION NO. 09/845,715	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)				APPLICANT JACKOWSKI et al.		FILING DATE 04/30/01	
				GROUP 1631			

U.S. PATENT DOCUMENTS							
EXAMINER'S INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	TRANSLATION	
CAL AG	5,538,897	07/96	Yates, III et al.	436	89	<div style="border: 1px solid black; padding: 2px; display: inline-block;"> RECEIVED DEC 11 2002 </div>	
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	YES	NO
CAL AG	WO 87/06344	10/87	PCT			X	
	WO 91/13352	09/91	PCT			X	
	WO 98/23290	07/98	PCT			X	
	WO 01/05422	01/01	PCT				X
CAL AG	WO 00/49410	08/00	PCT			X	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
CAL AG		Tang, et al., "Contribution of Renal Secreted Completed C3 to the Circulating Pool in Humans", Journal of Immunology (1999), Vol. 162, No. 7, pp. 4336-4341.
CAL		Koch, et al., "A Novel Polymorphism of Human Complement Component C3 Detected by Means of a Monoclonal Antibody", Immunogenetics (1986), Vol. 23, No. 5, pp. 322-325.
CAL		Beaudry, et al., "Complement C3 (C3F) As a Risk Factor for Stroke", Stroke (1990), Vol. 21, No. 1, p.168.
CAL		Muscari, et al., "Association of Serum C3 Levels With the Risk of Myocardial Infarction", American Journal of Medicine (1995), Vol. 98, No. 4, pp. 357-364.
CAL		Harrison et al., "Structure of C3f, a Small Peptide Specifically Released during Inactivation of the Third Component of Complement", Component (1988), Vol. 5, No. 1, pp. 27-32.
CAL		Agarwal, et al., "Immunologic Parameters in Infective Endocarditis: A Prospective Study", Indian Heart Journal (1991-05), Vol. 43, No. 3, pp. 179-183.
CAL		Kristensen, et al., "Association Between Coronary Heart Disease and the C3 ^F -Gene in Essential Hypertension", Circulation (1978), Vol. 58, No. 4, pp. 622-625.

EXAMINER	DATE CONSIDERED
	2/25/03 // 12/16/2005

* EXAMINER: Initial if a citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449

(Rev. 8-83)

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

2132.030

Serial No.

09/845,715

INFORMATION DISCLOSURE CITATION

FEB 11 2002

(Use several sheets if necessary)

Applicant

Jackowski et al.

Filing Date

04/30/01

Group

1645

RECEIVED

FEB 15 2002

TECH CENTER 1600/2300

U. S. PATENT DOCUMENTS

Examiner Initial	DOCUMENT NUMBER							Date	Name	Class	Subclass	Filing Date if Appropriate
cm	6	0	2	0	2	0	8	02/01/00	Hutchens et al	436	174	
cm	5	0	6	2	9	3	5	11/05/91	Schlag et al	204	157.41	

FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Translation Yes No
cm	WO 98/07036	02/19/98	PCT			X
cm	WO 90/14148	11/29/90	PCT			
cm	WO 93/24834	12/09/93	PCT			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

cm		Richter et al, Composition of the peptide fraction in human blood plasma: database of circulating human peptides, J. Chrom. B. Biomed. Sci. Appl., 726, 1-2, (1999), pp. 25-35.
cm		Takahashi et al, Rapid and sensitive immunoassay for the measurement of serum S100B using isoform-specific monoclonal antibody, Clin. Chem., 45, 8, (1999), pp. 1307-1311.
EXAMINER	DATE CONSIDERED	
	12/16/2005 2/25/03	

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.